Skip to content
Catalyst

O-acetyl-(R)-carnitineWhat was measured

Measured, with no finding

226 endpoints

Show what was measuredHide what was measured
  • ataxia clinical score, some symptoms

    decreases

    After the trial, we observed a statistically significant improvement of some symptoms and a slow progression of the disease in both groups of patients

    PMID 10803803 · one of two readings recorded this

  • blood urea nitrogen (BUN), serum ammonia, Glasgow Scale neurological findings and EEG grade in cirrhotic hepatic coma, LAC versus placebo

    Not recorded as a finding: the direction is carried only as a signed number

    Statistically significant differences in neurological findings, as evaluated by the Glasgow Scale, as well as in ammonia serum levels and BUN were found following LAC treatment.

    PMID 17080254 · one of two readings recorded this

  • BUN

    unclear

    Statistically significant differences in neurological findings, as evaluated by the Glasgow Scale, as well as in ammonia serum levels and BUN were found following LAC treatment

    PMID 17080254 · one of two readings recorded this

  • improved EEG grade (subjects)

    increases

    In the other group we observed an improvement of neurological findings and of EEG grade in 10 and 8 subjects, respectively

    PMID 17080254 · one of two readings recorded this

  • improved neurological findings (subjects)

    increases

    In the other group we observed an improvement of neurological findings and of EEG grade in 10 and 8 subjects, respectively

    PMID 17080254 · one of two readings recorded this

  • neurological findings (Glasgow Scale)

    increases

    Statistically significant differences in neurological findings, as evaluated by the Glasgow Scale, as well as in ammonia serum levels and BUN were found following LAC treatment

    PMID 17080254 · one of two readings recorded this

  • patients improving from grade 4 to grade 3

    increases

    Noteworthily, seven (54%) patients went from grade 4 down to grade 3, and one from grade 4 down to grade 1

    PMID 17080254 · one of two readings recorded this

  • serum ammonia

    unclear

    Statistically significant differences in neurological findings, as evaluated by the Glasgow Scale, as well as in ammonia serum levels and BUN were found following LAC treatment

    PMID 17080254 · one of two readings recorded this

  • hyperactivity on the Conners' Global Index Parents; social behaviour on the Vineland Adaptive Behavior Scale, in FXS boys with ADHD over one year

    decreases

    Not recorded as a finding: this platform holds no node for the endpoint

    However, we observed a stronger reduction of hyperactivity and improvement of social behavior in patients treated with LAC, compared with the placebo group, as determined by the Conners' Global Index Parents and the Vineland Adaptive Behavior Scale.

    PMID 18286595 · one of two readings recorded this

  • hyperactivity on the Conners' Global Index Parents; social behaviour on the Vineland Adaptive Behavior Scale

    decreases, stronger reduction of hyperactivity with LAC than placebo; no numeric estimate stated

    Not recorded as a finding: this platform holds no node for the endpoint

    However, we observed a stronger reduction of hyperactivity and improvement of social behavior in patients treated with LAC, compared with the placebo group, as determined by the Conners' Global Index Parents and the Vineland Adaptive Behavior Scale.

    PMID 18286595 · one of two readings recorded this

  • Hyperactivity

    decreases

    However, we observed a stronger reduction of hyperactivity and improvement of social behavior in patients treated with LAC, compared with the placebo group, as determined by the Conners' Global Index Parents and the Vineland Adaptive Behavior Scale

    PMID 18286595 · one of two readings recorded this

  • Social behavior

    increases

    However, we observed a stronger reduction of hyperactivity and improvement of social behavior in patients treated with LAC, compared with the placebo group, as determined by the Conners' Global Index Parents and the Vineland Adaptive Behavior Scale

    PMID 18286595 · one of two readings recorded this

  • EEG frequency

    increases, p = 0.001

    a significant improvement of EEG cps/s: 2.70 versus 0.6 P<0.001

    PMID 19357525 · one of two readings recorded this

  • serum ammonia levels (mumol); Glasgow Coma Scale score; EEG cps/s; blood urea nitrogen within-arm only

    decreases, 41.20 versus 10.40 mumol

    Not recorded as a finding: this platform holds no node for the endpoint

    After 60 min of the study period, the LAC+BCAA treated patients compared with BCCA treated showed a significant decrease of ammonia serum levels: 41.20 versus 10.40 mumol P<0.05.

    PMID 19357525 · one of two readings recorded this

  • serum ammonia (mumol), Glasgow Scale neurological score, EEG cps/s, blood urea nitrogen in cirrhotic hepatic coma; LAC+BCAA versus BCAA, both intravenous

    decreases, 41.20 versus 10.40 mumol

    Not recorded as a finding: this platform holds no node for the endpoint

    After 60 min of the study period, the LAC+BCAA treated patients compared with BCCA treated showed a significant decrease of ammonia serum levels: 41.20 versus 10.40 mumol P<0.05.

    PMID 19357525 · one of two readings recorded this

  • Serum ammonia

    decreases, p = 0.01

    a significant decrease of ammonia serum levels: 63.30 versus 27.00 mumol P<0.01

    PMID 19357525 · one of two readings recorded this

  • Serum ammonia

    decreases, p = 0.05

    After 60 min of the study period, the LAC+BCAA treated patients compared with BCCA treated showed a significant decrease of ammonia serum levels: 41.20 versus 10.40 mumol P<0.05

    PMID 19357525 · one of two readings recorded this

  • Insulin sensitivity (HOMA-IS) after therapy versus controls

    no effect

    nonstatistically different than controls after therapy (0.72+/-0.49 vs. 0.78+/-0.42)

    PMID 19598076 · one of two readings recorded this

  • Insulin sensitivity (HOMA-IS)

    decreases

    Insulin sensitivity was significantly lower prior (HOMA-IS 0.56+/-0.30)

    PMID 19598076 · one of two readings recorded this

  • intramyocellular triglyceride content of the soleus, (1)H NMR spectroscopy

    decreases, p = 0.03

    Not recorded as a finding: this platform holds no node for the endpoint

    After this therapy, in HIV-1 patients, the IMCL content of the soleus had significantly decreased (p=0.03).

    PMID 19598076 · one of two readings recorded this

  • intramyocellular triglyceride (IMCL) content of the soleus, (1)H NMR spectroscopy

    decreases, p = 0.03

    Not recorded as a finding: this platform holds no node for the endpoint

    After this therapy, in HIV-1 patients, the IMCL content of the soleus had significantly decreased (p=0.03).

    PMID 19598076 · one of two readings recorded this

  • Intramyocellular triglyceride (IMCL) content of the soleus

    decreases, p = 0.03

    After this therapy, in HIV-1 patients, the IMCL content of the soleus had significantly decreased (p=0.03)

    PMID 19598076 · one of two readings recorded this

  • Percentage of fat in the legs

    increases, p = 0.05

    the percentage of fat in the legs increased (p=0.05)

    PMID 19598076 · one of two readings recorded this

  • Plasma free fatty acids

    decreases, p = 0.05

    Plasma FFAs (0.79+/-0.31 to 0.64+/-0.25; p<0.05)

    PMID 19598076 · one of two readings recorded this

  • Respiratory quotient (lipid oxidation, indirect calorimetry)

    decreases, p = 0.03

    Respiratory Quotient (0.83+/-0.18 to 0.72+/-0.16; p<0.03) also decreased

    PMID 19598076 · one of two readings recorded this

  • degree of improvement, selegiline versus L-acetylcarnitine

    unclear

    The marked between-group differences demonstrate that, at the dosage used, selegiline was far more effective than L-acetylcarnitine with respect to the degree of improvement

    PMID 2121359 · one of two readings recorded this

  • global cognitive function (processing, storage and retrieval of information)

    increases

    selegiline therapy led to a global improvement in the capacity for the processing, storage, and retrieval of given information

    PMID 2121359 · one of two readings recorded this

  • psychometric battery (information processing, storage and retrieval, verbal fluency, visuospatial abilities) in mild-to-moderate Alzheimer-type disorders, selegiline vs L-acetylcarnitine

    selegiline far more effective than L-acetylcarnitine; no LAC-vs-untreated estimate

    Not recorded as a finding: the comparison was against another active treatment

    The marked between-group differences demonstrate that, at the dosage used, selegiline was far more effective than L-acetylcarnitine with respect to the degree of improvement.

    PMID 2121359 · one of two readings recorded this

  • verbal fluency and visuospatial abilities

    increases

    Improvements in verbal fluency and visuospatial abilities were also noted

    PMID 2121359 · one of two readings recorded this

  • Beck Depression Inventory score

    decreases

    Relief of depressive symptomatology is expressed by decreased scores in the Hamilton Rating Scale for Depression and Beck Depression Inventory and by beneficial effects with regard to behavioural aspects

    PMID 2205455 · one of two readings recorded this

  • behavioural aspects (Sandoz Clinical Assessment--Geriatric)

    unclear

    Relief of depressive symptomatology is expressed by decreased scores in the Hamilton Rating Scale for Depression and Beck Depression Inventory and by beneficial effects with regard to behavioural aspects

    PMID 2205455 · one of two readings recorded this

  • depressive symptoms on the Hamilton Rating Scale for Depression and the Beck Depression Inventory, LAC vs placebo, elderly patients

    decreases, decreased scores in the Hamilton Rating Scale for Depression and Beck Depression Inventory; no numeric estimate

    Not recorded as a finding: the supporting sentence never names the compound

    Relief of depressive symptomatology is expressed by decreased scores in the Hamilton Rating Scale for Depression and Beck Depression Inventory and by beneficial effects with regard to behavioural aspects.

    PMID 2205455 · one of two readings recorded this

  • Hamilton Rating Scale for Depression and Beck Depression Inventory scores in elderly depressed patients, LAC 500 mg three times daily versus placebo

    decreases

    Not recorded as a finding: the supporting sentence never names the compound

    Relief of depressive symptomatology is expressed by decreased scores in the Hamilton Rating Scale for Depression and Beck Depression Inventory and by beneficial effects with regard to behavioural aspects.

    PMID 2205455 · one of two readings recorded this

  • Hamilton Rating Scale for Depression score

    decreases

    Relief of depressive symptomatology is expressed by decreased scores in the Hamilton Rating Scale for Depression and Beck Depression Inventory and by beneficial effects with regard to behavioural aspects

    PMID 2205455 · one of two readings recorded this

  • Hyperactive behaviour, parents' assessment

    decreases, n = 17

    Parents' assessments favoured LAC in one study (MD -0.57, 95% CI -0.94 to -0.19, n = 17; low-quality evidence)

    PMID 25985235 · one of two readings recorded this

  • Hyperactive behaviour, parents' assessment

    no effect, n = 51

    but not in the other (MD -2.80, 95% CI -7.61 to 2.01, n = 51; low-quality evidence)

    PMID 25985235 · one of two readings recorded this

  • hyperactive behaviour, teacher-rated Conners' Abbreviated Parent-Teacher Questionnaire

    no effect, MD 0.50, 95% CI -5.08 to 6.08, n = 51

    Not recorded as a finding: this platform holds no node for the endpoint

    In one study, teachers' assessments of the children found no clear evidence of a difference (mean difference (MD) 0.50, 95% confidence interval (CI) -5.08 to 6.08, n = 51; low-quality evidence).

    PMID 25985235 · one of two readings recorded this

  • Hyperactive behaviour, teachers' assessment

    no effect, n = 51

    teachers' assessments of the children found no clear evidence of a difference (mean difference (MD) 0.50, 95% confidence interval (CI) -5.08 to 6.08, n = 51; low-quality evidence)

    PMID 25985235 · one of two readings recorded this

  • Verbal and non-verbal intellectual functioning

    no effect

    The authors did not provide detailed data on those results but said that they found no important differences between treatment and placebo

    PMID 25985235 · one of two readings recorded this

  • Vineland Adaptive Behavior composite

    no effect, n = 51

    one study reported no clear evidence of a difference in Vineland Adaptive Behavior composite scores (MD 8.20, 95% CI -0.02 to 16.42, n = 51; low-quality evidence)

    PMID 25985235 · one of two readings recorded this

  • Vineland Adaptive Behavior socialisation domain

    increases, n = 51

    results in the socialisation domain favoured LAC (MD 11.30, 95% CI 2.52 to 20.08, n = 51; low-quality evidence)

    PMID 25985235 · one of two readings recorded this

  • Body mass index

    BMI, kg/m2 | 30.0 ± 4.8 | 30.1 ± 5.0 | 30.0 ± 5.1 | 30.0 ± 5.2

    PMID 29696241 · one of two readings recorded this

  • Body mass index

    BMI, kg/m2 | 30.0 ± 4.8 | 30.1 ± 5.0 | 30.0 ± 5.1 | 30.0 ± 5.2

    PMID 29696241 · one of two readings recorded this

  • HDL cholesterol

    no effect

    HDL cholesterol, mg/dL | 45.0 ± 13.5 | 43.5 ± 14.0 | 44.9 ± 12.0 | 43.3 ± 12.4 a

    PMID 29696241 · one of two readings recorded this

  • HDL cholesterol

    decreases, p = 0.0174

    total and HDL cholesterol significantly increased and decreased from 155.7 ± 33.7 mg/dL to 161.3 ± 31.6 mg/dL (P = 0.0164) and from 44.9 ± 12.0 mg/dL to 43.3 ± 12.4 mg/dL (P = 0.0174)

    PMID 29696241 · one of two readings recorded this

  • HOMA-IR

    no effect

    Overall, GDR, HbA1c, and HOMA-IR did not significantly differ between the two treatments (Table 2)

    PMID 29696241 · one of two readings recorded this

  • HOMA-IR

    decreases, p = 0.0251

    from 3.1 (2.0 to 5.7) to 2.6 (1.7 to 4.8) (P = 0.0251) and from 3.3 (2.1 to 5.1) to 2.9 (1.7 to 5.2) (P = 0.0267)

    PMID 29696241 · one of two readings recorded this

  • HOMA-IR

    decreases, p = 0.0267

    from 3.1 (2.0 to 5.7) to 2.6 (1.7 to 4.8) (P = 0.0251) and from 3.3 (2.1 to 5.1) to 2.9 (1.7 to 5.2) (P = 0.0267)

    PMID 29696241 · one of two readings recorded this

  • LDL cholesterol

    LDL cholesterol, mg/dL | 101.5 ± 27.3 | 101.3 ± 22.8 | 103.0 ± 27.6 | 102.4 ± 22.8 | 84.9 ± 25.4 | 86.5 ± 27.0 | 80.0 ± 19.3 | 87.3 ± 24.0 b

    PMID 29696241 · one of two readings recorded this

  • LDL cholesterol

    LDL cholesterol, mg/dL | 101.5 ± 27.3 | 101.3 ± 22.8 | 103.0 ± 27.6 | 102.4 ± 22.8 | 84.9 ± 25.4 | 86.5 ± 27.0 | 80.0 ± 19.3 | 87.3 ± 24.0 b

    PMID 29696241 · one of two readings recorded this

  • LDL cholesterol

    increases

    LDL cholesterol, mg/dL | 101.5 ± 27.3 | 101.3 ± 22.8 | 103.0 ± 27.6 | 102.4 ± 22.8 | 84.9 ± 25.4 | 86.5 ± 27.0 | 80.0 ± 19.3 | 87.3 ± 24.0 b

    PMID 29696241 · one of two readings recorded this

  • LDL cholesterol

    LDL cholesterol, mg/dL | 101.5 ± 27.3 | 101.3 ± 22.8 | 103.0 ± 27.6 | 102.4 ± 22.8 | 84.9 ± 25.4 | 86.5 ± 27.0 | 80.0 ± 19.3 | 87.3 ± 24.0 b

    PMID 29696241 · one of two readings recorded this

  • LDL cholesterol

    no effect

    LDL cholesterol, mg/dL | 93.6 ± 27.6 | 94.3 ± 25.9 | 91.4 ± 26.4 | 94.8 ± 24.6

    PMID 29696241 · one of two readings recorded this

  • LDL cholesterol

    no effect

    LDL cholesterol, mg/dL | 93.6 ± 27.6 | 94.3 ± 25.9 | 91.4 ± 26.4 | 94.8 ± 24.6

    PMID 29696241 · one of two readings recorded this

  • Triglycerides

    no effect

    Triglycerides, mg/dL | 107.0 [83.0–143.0] | 107.0 [79.0–153.0] | 107.0 [74.0–148.0] | 111.0 [78.0–149.0]

    PMID 29696241 · one of two readings recorded this

  • Triglycerides

    no effect

    Triglycerides, mg/dL | 107.0 [83.0–143.0] | 107.0 [79.0–153.0] | 107.0 [74.0–148.0] | 111.0 [78.0–149.0]

    PMID 29696241 · one of two readings recorded this

  • Albuminuria

    no effect

    Albuminuria, μg/min | 8.0 [3.7–44.5] | 8.5 [3.5–39.5] | 9.0 [4.2–35.5] | 11.4 [3.6–45.2]

    PMID 29696241 · one of two readings recorded this

  • Albuminuria

    no effect

    Albuminuria, μg/min | 8.0 [3.7–44.5] | 8.5 [3.5–39.5] | 9.0 [4.2–35.5] | 11.4 [3.6–45.2]

    PMID 29696241 · one of two readings recorded this

  • Body weight

    Weight, kg | 83.0 ± 14.4 | 83.1 ± 14.8 | 84.6 ± 15.5 | 84.4 ± 15.6

    PMID 29696241 · one of two readings recorded this

  • Body weight

    Weight, kg | 83.0 ± 14.4 | 83.1 ± 14.8 | 84.6 ± 15.5 | 84.4 ± 15.6

    PMID 29696241 · one of two readings recorded this

  • Diastolic blood pressure

    no effect, p = 0.8994

    Overall, the effect of ALC on DBP was not significantly different from that of placebo (P = 0.8994)

    PMID 29696241 · one of two readings recorded this

  • Diastolic blood pressure

    DBP, mm Hg | 78.8 ± 6.6 | 77.4 ± 7.4 | 78.8 ± 10.3 | 78.7 ± 9.9 | 81.2 ± 6.6 | 79.5 ± 7.5 | 79.9 ± 9.7 | 77.8 ± 8.3

    PMID 29696241 · one of two readings recorded this

  • Diastolic blood pressure

    DBP, mm Hg | 78.8 ± 6.6 | 77.4 ± 7.4 | 78.8 ± 10.3 | 78.7 ± 9.9 | 81.2 ± 6.6 | 79.5 ± 7.5 | 79.9 ± 9.7 | 77.8 ± 8.3

    PMID 29696241 · one of two readings recorded this

  • Diastolic blood pressure

    DBP, mm Hg | 78.8 ± 6.6 | 77.4 ± 7.4 | 78.8 ± 10.3 | 78.7 ± 9.9 | 81.2 ± 6.6 | 79.5 ± 7.5 | 79.9 ± 9.7 | 77.8 ± 8.3

    PMID 29696241 · one of two readings recorded this

  • Diastolic blood pressure

    DBP, mm Hg | 78.8 ± 6.6 | 77.4 ± 7.4 | 78.8 ± 10.3 | 78.7 ± 9.9 | 81.2 ± 6.6 | 79.5 ± 7.5 | 79.9 ± 9.7 | 77.8 ± 8.3

    PMID 29696241 · one of two readings recorded this

  • Diastolic blood pressure

    decreases, p = 0.0387

    whereas DBP was significantly reduced after 6 months of ALC (from 79.9 ± 6.7 to 78.4 ± 7.5; P = 0.0387)

    PMID 29696241 · one of two readings recorded this

  • Diastolic blood pressure

    no effect

    DBP, mm Hg | 79.9 ± 6.7 | 78.4 ± 7.5 a | 79.4 ± 10.0 | 78.2 ± 9.1

    PMID 29696241 · one of two readings recorded this

  • glomerular filtration rate by iohexol plasma clearance, and albuminuria by overnight rate nephelometry

    no effect

    Not recorded as a finding: sentence is a within-arm statement ('neither ALC nor placebo significantly affected'); measured GFR is not an eGFR from an equation, albuminuria in ug/min is not matched to a node requirement here

    Throughout the study neither ALC nor placebo significantly affected kidney function (including directly measured GFR) and albuminuria (Table 2).

    PMID 29696241 · one of two readings recorded this

  • Glomerular filtration rate

    no effect

    GFR, mL/min/1.73 m2 d | 97.2 ± 22.1 | 96.4 ± 22.4 | 101.3 ± 27.0 | 99.8 ± 26.1

    PMID 29696241 · one of two readings recorded this

  • Glomerular filtration rate

    no effect

    GFR, mL/min/1.73 m2 d | 97.2 ± 22.1 | 96.4 ± 22.4 | 101.3 ± 27.0 | 99.8 ± 26.1

    PMID 29696241 · one of two readings recorded this

  • Glucose disposal rate

    no effect

    Overall, GDR, HbA1c, and HOMA-IR did not significantly differ between the two treatments (Table 2)

    PMID 29696241 · one of two readings recorded this

  • Glucose disposal rate

    GDR, mg/kg/min c | 5.7 [4.2–8.4] | 5.5 [4.9–7.2] | 5.7 [4.6–7.2] | 6.0 [4.9–7.6]

    PMID 29696241 · one of two readings recorded this

  • Glucose disposal rate

    GDR, mg/kg/min c | 5.7 [4.2–8.4] | 5.5 [4.9–7.2] | 5.7 [4.6–7.2] | 6.0 [4.9–7.6]

    PMID 29696241 · one of two readings recorded this

  • HbA1c (HPLC) and HOMA-IR, between-arm comparison

    no effect

    Not recorded as a finding: the only between-arm sentence is agentless ('the two treatments') and does not name ALC; rule 1

    Overall, GDR, HbA1c, and HOMA-IR did not significantly differ between the two treatments (Table 2).

    PMID 29696241 · one of two readings recorded this

  • HbA1c, HPLC, between-arm change at 6 months

    no effect

    Not recorded as a finding: the only between-arm sentence says 'the two treatments' and never names ALC (rule 1: sentence must name the compound)

    Overall, GDR, HbA1c, and HOMA-IR did not significantly differ between the two treatments (Table 2).

    PMID 29696241 · one of two readings recorded this

  • HbA1c (mmol/mol)

    increases, p = 0.0007

    from 51.1 ± 14.0 mmol/mol to 54.4 ± 15.2 mmol/mol (P = 0.0007) and from 50.5 ± 12.2 mmol/mol to 53.0 ± 14.0 mmol/mol (P = 0.0230)

    PMID 29696241 · one of two readings recorded this

  • HbA1c (mmol/mol)

    increases, p = 0.023

    from 51.1 ± 14.0 mmol/mol to 54.4 ± 15.2 mmol/mol (P = 0.0007) and from 50.5 ± 12.2 mmol/mol to 53.0 ± 14.0 mmol/mol (P = 0.0230)

    PMID 29696241 · one of two readings recorded this

  • HbA1c

    no effect

    Overall, GDR, HbA1c, and HOMA-IR did not significantly differ between the two treatments (Table 2)

    PMID 29696241 · one of two readings recorded this

  • HbA1c (%)

    increases

    HbA1c, % | 7.0 ± 1.18 | 7.1 ± 1.19 | 7.0 ± 1.16 | 7.0 ± 1.45 | 6.6 ± 1.36 | 7.2 ± 1.58 b | 6.6 ± 1.05 | 7.0 ± 1.10 b

    PMID 29696241 · one of two readings recorded this

  • HbA1c (%)

    HbA1c, % | 7.0 ± 1.18 | 7.1 ± 1.19 | 7.0 ± 1.16 | 7.0 ± 1.45 | 6.6 ± 1.36 | 7.2 ± 1.58 b | 6.6 ± 1.05 | 7.0 ± 1.10 b

    PMID 29696241 · one of two readings recorded this

  • HbA1c (%)

    increases

    HbA1c, % | 7.0 ± 1.18 | 7.1 ± 1.19 | 7.0 ± 1.16 | 7.0 ± 1.45 | 6.6 ± 1.36 | 7.2 ± 1.58 b | 6.6 ± 1.05 | 7.0 ± 1.10 b

    PMID 29696241 · one of two readings recorded this

  • HbA1c (%)

    HbA1c, % | 7.0 ± 1.18 | 7.1 ± 1.19 | 7.0 ± 1.16 | 7.0 ± 1.45 | 6.6 ± 1.36 | 7.2 ± 1.58 b | 6.6 ± 1.05 | 7.0 ± 1.10 b

    PMID 29696241 · one of two readings recorded this

  • HbA1c (%)

    HbA1c, % | 6.8 ± 1.28 | 7.1 ± 1.39 b | 6.8 ± 1.12 | 7.0 ± 1.28 a

    PMID 29696241 · one of two readings recorded this

  • HbA1c (%)

    HbA1c, % | 6.8 ± 1.28 | 7.1 ± 1.39 b | 6.8 ± 1.12 | 7.0 ± 1.28 a

    PMID 29696241 · one of two readings recorded this

  • HOMA-IR, fasting glucose (mg/dL) times insulin (uIU/mL) over 405

    no effect

    Not recorded as a finding: the only between-arm sentence says 'the two treatments' and never names ALC

    Overall, GDR, HbA1c, and HOMA-IR did not significantly differ between the two treatments (Table 2).

    PMID 29696241 · one of two readings recorded this

  • Insulin

    Insulin, µIU/mL | 8.7 [6.4–14.5] | 7.8 [5.4–12.4] | 8.9 [6.0–14.6] | 8.5 [5.4–14.2]

    PMID 29696241 · one of two readings recorded this

  • Insulin

    Insulin, µIU/mL | 8.7 [6.4–14.5] | 7.8 [5.4–12.4] | 8.9 [6.0–14.6] | 8.5 [5.4–14.2]

    PMID 29696241 · one of two readings recorded this

  • lipoprotein(a), nephelometry

    no effect

    Not recorded as a finding: no outcome node for lipoprotein(a)

    The effect of ALC on triglycerides, lipoprotein(a), LDL, HDL, and total cholesterol was not significantly different from that of placebo.

    PMID 29696241 · one of two readings recorded this

  • Lipoprotein(a)

    no effect

    Lipoprotein(a), µIU/mL | 8.9 [3.7–35.0] | 9.0 [3.0–44.2] | 11.5 [3.6–28.7] | 11.3 [4.3–32.5]

    PMID 29696241 · one of two readings recorded this

  • Lipoprotein(a)

    no effect

    Lipoprotein(a), µIU/mL | 8.9 [3.7–35.0] | 9.0 [3.0–44.2] | 11.5 [3.6–28.7] | 11.3 [4.3–32.5]

    PMID 29696241 · one of two readings recorded this

  • Mean blood pressure

    Mean BP, mm Hg | 98.4 ± 7.5 | 96.7 ± 7.7 a | 98.9 ± 11.1 | 97.0 ± 9.8 a

    PMID 29696241 · one of two readings recorded this

  • Mean blood pressure

    Mean BP, mm Hg | 98.4 ± 7.5 | 96.7 ± 7.7 a | 98.9 ± 11.1 | 97.0 ± 9.8 a

    PMID 29696241 · one of two readings recorded this

  • overnight urinary albumin excretion, rate nephelometry; GFR by iohexol plasma clearance

    no effect

    Not recorded as a finding: the sentence reports 'neither ALC nor placebo' affected them, a within-arm statement, not a between-arm contrast; GFR was measured, not estimated, so the egfr node does not fit

    Throughout the study neither ALC nor placebo significantly affected kidney function (including directly measured GFR) and albuminuria (Table 2).

    PMID 29696241 · one of two readings recorded this

  • Serum creatinine

    no effect

    Serum creatinine, mg/dL | 0.93 ± 0.2 | 0.93 ± 0.2 | 0.94 ± 0.2 | 0.95 ± 0.2

    PMID 29696241 · one of two readings recorded this

  • Serum creatinine

    no effect

    Serum creatinine, mg/dL | 0.93 ± 0.2 | 0.93 ± 0.2 | 0.94 ± 0.2 | 0.95 ± 0.2

    PMID 29696241 · one of two readings recorded this

  • Serum glucose

    Serum glucose | 147.2 ± 41.7 | 144.0 ± 42.1 | 155.0 ± 42.1 | 146.5 ± 46.2

    PMID 29696241 · one of two readings recorded this

  • Serum glucose

    Serum glucose | 147.2 ± 41.7 | 144.0 ± 42.1 | 155.0 ± 42.1 | 146.5 ± 46.2

    PMID 29696241 · one of two readings recorded this

  • Systolic blood pressure

    no effect, p = 0.9539

    SBP was not significantly different after 6 months of treatment with ALC or placebo, even after adjustment for baseline values (P = 0.9539)

    PMID 29696241 · one of two readings recorded this

  • Systolic blood pressure

    SBP, mm Hg | 136.2 ± 13.0 | 134. 0 ± 13.7 | 138.6 ± 19.3 | 135.8 ± 16.4 | 134.6 ± 14.9 | 132.6 ± 13.9 | 137.6 ± 17.4 | 133.2 ± 13.6 a

    PMID 29696241 · one of two readings recorded this

  • Systolic blood pressure

    SBP, mm Hg | 136.2 ± 13.0 | 134. 0 ± 13.7 | 138.6 ± 19.3 | 135.8 ± 16.4 | 134.6 ± 14.9 | 132.6 ± 13.9 | 137.6 ± 17.4 | 133.2 ± 13.6 a

    PMID 29696241 · one of two readings recorded this

  • Systolic blood pressure

    decreases, p = 0.015

    in the short-term statin therapy, SBP significantly decreased only when patients took placebo (137.6 ± 17.4 mm Hg to 133.2 ± 13.6 mm Hg; P = 0.015)

    PMID 29696241 · one of two readings recorded this

  • Systolic blood pressure

    SBP, mm Hg | 136.2 ± 13.0 | 134. 0 ± 13.7 | 138.6 ± 19.3 | 135.8 ± 16.4 | 134.6 ± 14.9 | 132.6 ± 13.9 | 137.6 ± 17.4 | 133.2 ± 13.6 a

    PMID 29696241 · one of two readings recorded this

  • Systolic blood pressure

    no effect

    SBP, mm Hg | 135.4 ± 13.9 | 133.3 ± 13.7 | 138.1 ± 18.3 | 134.5 ± 15.1 a

    PMID 29696241 · one of two readings recorded this

  • Systolic blood pressure

    decreases, p = 0.0187

    it significantly decreased in patients allocated to placebo (from 138.1 ± 18.3 mm Hg to 134.5 ± 15.1 mm Hg; P = 0.0187)

    PMID 29696241 · one of two readings recorded this

  • Total cholesterol

    Total cholesterol, mg/dL | 167.9 ± 32.4 | 168.8 ± 30.2 | 170.7 ± 35.7 | 171.3 ± 32.4 | 148.4 ± 27.8 | 151.8 ± 30.4 | 141.0 ± 24.0 | 151.3 ± 27.6 b

    PMID 29696241 · one of two readings recorded this

  • Total cholesterol

    Total cholesterol, mg/dL | 167.9 ± 32.4 | 168.8 ± 30.2 | 170.7 ± 35.7 | 171.3 ± 32.4 | 148.4 ± 27.8 | 151.8 ± 30.4 | 141.0 ± 24.0 | 151.3 ± 27.6 b

    PMID 29696241 · one of two readings recorded this

  • Total cholesterol

    increases

    Total cholesterol, mg/dL | 167.9 ± 32.4 | 168.8 ± 30.2 | 170.7 ± 35.7 | 171.3 ± 32.4 | 148.4 ± 27.8 | 151.8 ± 30.4 | 141.0 ± 24.0 | 151.3 ± 27.6 b

    PMID 29696241 · one of two readings recorded this

  • Total cholesterol

    Total cholesterol, mg/dL | 167.9 ± 32.4 | 168.8 ± 30.2 | 170.7 ± 35.7 | 171.3 ± 32.4 | 148.4 ± 27.8 | 151.8 ± 30.4 | 141.0 ± 24.0 | 151.3 ± 27.6 b

    PMID 29696241 · one of two readings recorded this

  • Total cholesterol

    no effect

    Total cholesterol, mg/dL | 158.6 ± 31.7 | 160.7 ± 31.2 | 155.7 ± 33.7 | 161.3 ± 31.6 a

    PMID 29696241 · one of two readings recorded this

  • Total cholesterol

    increases, p = 0.0164

    total and HDL cholesterol significantly increased and decreased from 155.7 ± 33.7 mg/dL to 161.3 ± 31.6 mg/dL (P = 0.0164) and from 44.9 ± 12.0 mg/dL to 43.3 ± 12.4 mg/dL (P = 0.0174)

    PMID 29696241 · one of two readings recorded this

  • adverse events, proportion of patients with any adverse event

    13.3% ALC vs 7.7% placebo

    Not recorded as a finding: supplement-adverse-event-incidence node requires event proportion; the sentence gives two proportions with no between-arm test or two-sided statement

    The proportion of patients with AE was 13.3% in ALC-treated group, and 7.7% in placebo-treated group respectively (Table 5).

    PMID 30906386 · one of two readings recorded this

  • CDR-SB

    unclear, p = 0.029

    CDR-SB | 0.029†

    PMID 30906386 · one of two readings recorded this

  • CDR-SB

    ALC | 4.7±1.2 | 4.6±1.1 | 4.2±1.3

    PMID 30906386 · one of two readings recorded this

  • CDR-SB

    ALC | 4.7±1.2 | 4.6±1.1 | 4.2±1.3

    PMID 30906386 · one of two readings recorded this

  • CDR-SB

    Placebo | 4.7±1.2 | 4.5±0.9 | 4.4±1.2

    PMID 30906386 · one of two readings recorded this

  • CDR-SB

    Placebo | 4.7±1.2 | 4.5±0.9 | 4.4±1.2

    PMID 30906386 · one of two readings recorded this

  • Clinical Dementia Rating Sum of Boxes (CDR-SB), global clinical rating

    no effect

    Not recorded as a finding: no_outcome_node: no CDR-SB node in the outcome list

    Global cognitive impression scales such as CDR, and CDR-SB also showed non-significant changes between ALC- and placebo-treated groups (Table 2).

    PMID 30906386 · one of two readings recorded this

  • COWAT

    no effect, p = 0.403

    COWAT | 0.403

    PMID 30906386 · one of two readings recorded this

  • COWAT

    ALC | 34.5±13.0 | 35.5±15.1 | 37.6±15.3

    PMID 30906386 · one of two readings recorded this

  • COWAT

    ALC | 34.5±13.0 | 35.5±15.1 | 37.6±15.3

    PMID 30906386 · one of two readings recorded this

  • COWAT

    Placebo | 31.4±10.0 | 34.6±14.0 | 33.8±15.3

    PMID 30906386 · one of two readings recorded this

  • COWAT

    Placebo | 31.4±10.0 | 34.6±14.0 | 33.8±15.3

    PMID 30906386 · one of two readings recorded this

  • CWST color correct

    no effect, p = 0.85

    CWST color correct | 0.850

    PMID 30906386 · one of two readings recorded this

  • CWST color correct

    ALC | 97.5±33.6 | 97.9±32.0 | 97.9±32.3

    PMID 30906386 · one of two readings recorded this

  • CWST color correct

    ALC | 97.5±33.6 | 97.9±32.0 | 97.9±32.3

    PMID 30906386 · one of two readings recorded this

  • CWST color correct

    Placebo | 94.1±35.4 | 93.2±34.7 | 94.1±32.3

    PMID 30906386 · one of two readings recorded this

  • CWST color correct

    Placebo | 94.1±35.4 | 93.2±34.7 | 94.1±32.3

    PMID 30906386 · one of two readings recorded this

  • CWST color incorrect

    no effect, p = 0.302

    CWST color incorrect | 0.302

    PMID 30906386 · one of two readings recorded this

  • CWST color incorrect

    ALC | 13.1±25.5 | 12.3±20.9 | 14.1±21.4

    PMID 30906386 · one of two readings recorded this

  • CWST color incorrect

    ALC | 13.1±25.5 | 12.3±20.9 | 14.1±21.4

    PMID 30906386 · one of two readings recorded this

  • CWST color incorrect

    Placebo | 20.4±26.8 | 20.6±25.4 | 19.6±28.0

    PMID 30906386 · one of two readings recorded this

  • CWST color incorrect

    Placebo | 20.4±26.8 | 20.6±25.4 | 19.6±28.0

    PMID 30906386 · one of two readings recorded this

  • CWST word correct

    no effect, p = 0.732

    CWST word correct | 0.732

    PMID 30906386 · one of two readings recorded this

  • CWST word correct

    ALC | 107.9±15.5 | 108.1±14.0 | 109.6±12.4

    PMID 30906386 · one of two readings recorded this

  • CWST word correct

    ALC | 107.9±15.5 | 108.1±14.0 | 109.6±12.4

    PMID 30906386 · one of two readings recorded this

  • CWST word correct

    Placebo | 100.7±15.5 | 100.9±27.6 | 100.7±28.0

    PMID 30906386 · one of two readings recorded this

  • CWST word correct

    Placebo | 100.7±15.5 | 100.9±27.6 | 100.7±28.0

    PMID 30906386 · one of two readings recorded this

  • CWST word incorrect

    no effect, p = 0.753

    CWST word incorrect | 0.753

    PMID 30906386 · one of two readings recorded this

  • CWST word incorrect

    ALC | 3.3±10.0 | 3.9±9.9 | 3.4±11.4

    PMID 30906386 · one of two readings recorded this

  • CWST word incorrect

    ALC | 3.3±10.0 | 3.9±9.9 | 3.4±11.4

    PMID 30906386 · one of two readings recorded this

  • CWST word incorrect

    Placebo | 12.7±16.8 | 12.3±20.4 | 11.7±28.0

    PMID 30906386 · one of two readings recorded this

  • CWST word incorrect

    Placebo | 12.7±16.8 | 12.3±20.4 | 11.7±28.0

    PMID 30906386 · one of two readings recorded this

  • GDS

    no effect, p = 0.973

    GDS | 0.973

    PMID 30906386 · one of two readings recorded this

  • GDS

    ALC | 12.8±5.4 | 13.9±5.1 | 13.6±5.1

    PMID 30906386 · one of two readings recorded this

  • GDS

    ALC | 12.8±5.4 | 13.9±5.1 | 13.6±5.1

    PMID 30906386 · one of two readings recorded this

  • GDS

    Placebo | 13.8±5.1 | 14.7±5.7 | 14.5±5.2

    PMID 30906386 · one of two readings recorded this

  • GDS

    Placebo | 13.8±5.1 | 14.7±5.7 | 14.5±5.2

    PMID 30906386 · one of two readings recorded this

  • Geriatric Depression Scale (GDS) score

    no effect

    Not recorded as a finding: no_outcome_node: no Geriatric Depression Scale node in the outcome list

    Cognitive assessment tools such as K-MMSE, K-CWST, COWAT, K-TMT-E, and GDS, K-IADL showed no significant differences between ALC- and placebo-treated groups (Tables 2 and 4).

    PMID 30906386 · one of two readings recorded this

  • K-IADL

    unclear, p = 0.003

    K-IADL | 0.003†

    PMID 30906386 · one of two readings recorded this

  • K-IADL

    ALC | 10.7±5.1 | 10.6±10.2 | 9.7±9.6

    PMID 30906386 · one of two readings recorded this

  • K-IADL

    ALC | 10.7±5.1 | 10.6±10.2 | 9.7±9.6

    PMID 30906386 · one of two readings recorded this

  • K-IADL

    Placebo | 13.5±6.9 | 9.6±7.0 | 9.3±10.1

    PMID 30906386 · one of two readings recorded this

  • K-IADL

    Placebo | 13.5±6.9 | 9.6±7.0 | 9.3±10.1

    PMID 30906386 · one of two readings recorded this

  • K-MMSE

    no effect, p = 0.819

    K-MMSE | 0.819

    PMID 30906386 · one of two readings recorded this

  • K-MMSE

    ALC | 21.5±2.7 | 21.6±3.5 | 21.6±3.6

    PMID 30906386 · one of two readings recorded this

  • K-MMSE

    ALC | 21.5±2.7 | 21.6±3.5 | 21.6±3.6

    PMID 30906386 · one of two readings recorded this

  • K-MMSE

    Placebo | 21.1±2.4 | 21.1±2.7 | 21.1±2.9

    PMID 30906386 · one of two readings recorded this

  • K-MMSE

    Placebo | 21.1±2.4 | 21.1±2.7 | 21.1±2.9

    PMID 30906386 · one of two readings recorded this

  • K-TMT-E status

    no effect, p = 0.117

    ALC | 0.117

    PMID 30906386 · one of two readings recorded this

  • MoCA-K abstract sub-item

    no effect, p = 0.443

    Abstract | 0.443

    PMID 30906386 · one of two readings recorded this

  • MoCA-K abstract sub-item

    ALC | 0.8±0.6 | 0.9±0.8 | 0.9±0.6

    PMID 30906386 · one of two readings recorded this

  • MoCA-K abstract sub-item

    ALC | 0.8±0.6 | 0.9±0.8 | 0.9±0.6

    PMID 30906386 · one of two readings recorded this

  • MoCA-K abstract sub-item

    Placebo | 0.8±0.7 | 0.8±0.7 | 1.1±0.6

    PMID 30906386 · one of two readings recorded this

  • MoCA-K abstract sub-item

    Placebo | 0.8±0.7 | 0.8±0.7 | 1.1±0.6

    PMID 30906386 · one of two readings recorded this

  • MoCA-K attention sub-item

    unclear, p = 0.025

    Attention* | 0.025

    PMID 30906386 · one of two readings recorded this

  • MoCA-K attention sub-item

    ALC | 3.7±1.4 | 3.7±1.1 | 3.5±1.5

    PMID 30906386 · one of two readings recorded this

  • MoCA-K attention sub-item

    ALC | 3.7±1.4 | 3.7±1.1 | 3.5±1.5

    PMID 30906386 · one of two readings recorded this

  • MoCA-K attention sub-item

    Placebo | 4.1±1.7 | 3.5±1.3 | 3.3±1.3

    PMID 30906386 · one of two readings recorded this

  • MoCA-K attention sub-item

    Placebo | 4.1±1.7 | 3.5±1.3 | 3.3±1.3

    PMID 30906386 · one of two readings recorded this

  • MoCA-K delayed recall sub-item

    no effect, p = 0.1

    Delayed recall | 0.100

    PMID 30906386 · one of two readings recorded this

  • MoCA-K delayed recall sub-item

    ALC | 0.9±0.9 | 1.1±0.7 | 1.3±0.8

    PMID 30906386 · one of two readings recorded this

  • MoCA-K delayed recall sub-item

    ALC | 0.9±0.9 | 1.1±0.7 | 1.3±0.8

    PMID 30906386 · one of two readings recorded this

  • MoCA-K delayed recall sub-item

    Placebo | 1.2±1.0 | 1.2±0.9 | 1.2±0.9

    PMID 30906386 · one of two readings recorded this

  • MoCA-K delayed recall sub-item

    Placebo | 1.2±1.0 | 1.2±0.9 | 1.2±0.9

    PMID 30906386 · one of two readings recorded this

  • MoCA-K language sub-item

    increases, p = 0.012

    Language* | 0.012

    PMID 30906386 · one of two readings recorded this

  • MoCA-K language sub-item

    ALC | 1.4±0.9 | 1.5±1.0 | 1.9±0.8

    PMID 30906386 · one of two readings recorded this

  • MoCA-K language sub-item

    ALC | 1.4±0.9 | 1.5±1.0 | 1.9±0.8

    PMID 30906386 · one of two readings recorded this

  • MoCA-K language sub-item

    Placebo | 1.3±0.8 | 1.8±1.0 | 1.5±0.7

    PMID 30906386 · one of two readings recorded this

  • MoCA-K language sub-item

    Placebo | 1.3±0.8 | 1.8±1.0 | 1.5±0.7

    PMID 30906386 · one of two readings recorded this

  • MoCA-K naming sub-item

    no effect, p = 0.31

    Naming | 0.310

    PMID 30906386 · one of two readings recorded this

  • MoCA-K naming sub-item

    ALC | 2.5±0.7 | 2.5±0.8 | 2.5±0.8

    PMID 30906386 · one of two readings recorded this

  • MoCA-K naming sub-item

    ALC | 2.5±0.7 | 2.5±0.8 | 2.5±0.8

    PMID 30906386 · one of two readings recorded this

  • MoCA-K naming sub-item

    Placebo | 2.4±1.0 | 2.2±1.1 | 2.3±1.1

    PMID 30906386 · one of two readings recorded this

  • MoCA-K naming sub-item

    Placebo | 2.4±1.0 | 2.2±1.1 | 2.3±1.1

    PMID 30906386 · one of two readings recorded this

  • MoCA-K orientation sub-item

    unclear

    Orientation† | 0.000

    PMID 30906386 · one of two readings recorded this

  • MoCA-K orientation sub-item

    ALC | 4.7±1.4 | 4.2±1.5 | 4.1±1.3

    PMID 30906386 · one of two readings recorded this

  • MoCA-K orientation sub-item

    ALC | 4.7±1.4 | 4.2±1.5 | 4.1±1.3

    PMID 30906386 · one of two readings recorded this

  • MoCA-K orientation sub-item

    Placebo | 4.3±1.3 | 4.0±1.4 | 3.8±1.3

    PMID 30906386 · one of two readings recorded this

  • MoCA-K orientation sub-item

    Placebo | 4.3±1.3 | 4.0±1.4 | 3.8±1.3

    PMID 30906386 · one of two readings recorded this

  • MoCA-K total

    increases, p = 0.01

    MoCA-K | 0.010*

    PMID 30906386 · one of two readings recorded this

  • MoCA-K total

    ALC | 17.3±4.1 | 17.2±4.0 | 17.6±4.2

    PMID 30906386 · one of two readings recorded this

  • MoCA-K total

    ALC | 17.3±4.1 | 17.2±4.0 | 17.6±4.2

    PMID 30906386 · one of two readings recorded this

  • MoCA-K total

    Placebo | 16.7±3.8 | 16.3±3.1 | 15.9±3.8

    PMID 30906386 · one of two readings recorded this

  • MoCA-K total

    Placebo | 16.7±3.8 | 16.3±3.1 | 15.9±3.8

    PMID 30906386 · one of two readings recorded this

  • MoCA-K visuospatial sub-item

    no effect, p = 0.565

    Visuospatial | 0.565

    PMID 30906386 · one of two readings recorded this

  • MoCA-K visuospatial sub-item

    ALC | 2.8±1.4 | 2.9±1.4 | 3.0±1.3

    PMID 30906386 · one of two readings recorded this

  • MoCA-K visuospatial sub-item

    ALC | 2.8±1.4 | 2.9±1.4 | 3.0±1.3

    PMID 30906386 · one of two readings recorded this

  • MoCA-K visuospatial sub-item

    Placebo | 2.3±1.4 | 2.4±1.3 | 2.4±1.3

    PMID 30906386 · one of two readings recorded this

  • MoCA-K visuospatial sub-item

    Placebo | 2.3±1.4 | 2.4±1.3 | 2.4±1.3

    PMID 30906386 · one of two readings recorded this

  • proportion of patients with any adverse event, tallied from the trial's AE records

    Not recorded as a finding: no direction word and no between-arm test in the sentence; supplement-adverse-event-incidence needs a stated direction

    The proportion of patients with AE was 13.3% in ALC-treated group, and 7.7% in placebo-treated group respectively (Table 5).

    PMID 30906386 · one of two readings recorded this

The whole record — 226 rows